Our case reports are the first to describe two chronic phase CML patients with typical e13a2 and e14a2 BCR::ABL1 transcripts who maintained a stable TFR for at least 8 months after discontinuing asciminib. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.